Plasma N-glycans in colorectal cancer risk (CROSBI ID 265114)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Doherty, Margaret ; Theodoratou, Evropi ; Walsh, Ian ; Adamczyk, Barbara ; Stöckmann, Henning ; Agakov, Felix ; Timofeeva, Maria ; Trbojević-Akmačić, Irena ; Vučković, Frano ; Duffy, Fergal ; McManus, Ciara A. ; Farrington, Susan M. ; Dunlop, Malcolm G. ; Perola, Markus ; Lauc, Gordan ; Campbell, Harry ; Rudd, Pauline M.
engleski
Plasma N-glycans in colorectal cancer risk
Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.
glycosylation, crc
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Biologija, Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti